Latest Period
Q2 2026
Security Snapshot
Generate Biomedicines, Inc. - Common Stock, $0.001 par value per share (GENB) Institutional Ownership
CUSIP: 370920100
13F Institutional Holders and Ownership History from Q1 2026 to Q2 2026
Institutions Reporting
86
Shares (Excl. Options)
100,045,749
Price
$16.87
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- GENB on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 100,045,749
- Total 13F value
- $1,687,831,069
- Portfolio coverage rank
- 0%
- Share change
- +7,217,567
- Value change
- +$127,781,759
- Number of holders
- 86
- Shares outstanding
- 128,224,775
- SEC-reported price per share
- $14.03
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GENB - Generate Biomedicines, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 370920100.
- 86 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 57 to 86 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,157,381,584 to $1,687,831,069.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 86 institutions filings for Q2 2026.
Security key
370920100
Latest holder period
Q2 2026
13F holders
86
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
GENB full holder history
Generate Biomedicines, Inc. SEC filings
Generate Biomedicines, Inc. company facts
Generate Biomedicines, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 370920100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
GENB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Flagship Pioneering, LLC | 49% | $802,584,512 | 62,701,915 | Afeyan Noubar | 31 Mar 2026 | |||
| Nally Michael | 5.2% | $88,563,853 | 6,919,051 | Nally Michael | 31 Mar 2026 |
As of 30 Jun 2026, 86 institutional investors reported holding 100,045,749 shares of Generate Biomedicines, Inc. - Common Stock, $0.001 par value per share (GENB). This represents 78% of the company’s total 128,224,775 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
76%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Flagship Pioneering, LLC | 49% | 62,673,117 | 0% | 69% | $1,057,295,483 |
| FMR LLC | 4.1% | 5,221,599 | +24% | 0% | $88,088,375 |
| Capital World Investors | 3.3% | 4,215,632 | +5.3% | 0.01% | $71,117,712 |
| BRAIDWELL LP | 2.6% | 3,283,844 | -8.6% | 2% | $55,398,448 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.7% | 2,156,627 | +2.2% | 0% | $36,383,000 |
| NORGES BANK | 1.6% | 2,094,616 | 0% | $35,336,172 | |
| ARCH Venture Management, LLC | 1.5% | 1,944,426 | 0% | 3% | $32,802,467 |
| HarbourVest Partners LLC | 1.3% | 1,722,210 | 0% | 17% | $29,053,683 |
| BlackRock, Inc. | 1.3% | 1,659,966 | 0% | $28,003,627 | |
| BAKER BROS. ADVISORS LP | 1.1% | 1,423,602 | 0% | 0.12% | $24,016,166 |
| JPMORGAN CHASE & CO | 1.1% | 1,409,649 | -52% | 0% | $23,837,165 |
| Deep Track Capital, LP | 1% | 1,333,815 | 0.33% | $22,501,459 | |
| ARK Investment Management LLC | 1% | 1,284,617 | +158% | 0.14% | $21,671,492 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.88% | 1,132,750 | +763% | 0% | $19,109,493 |
| HARVARD MANAGEMENT CO INC | 0.87% | 1,111,100 | 0% | 0.44% | $18,744,257 |
| NVIDIA CORP | 0.65% | 833,325 | 0% | 0.02% | $14,058,193 |
| Davern Capital Partners, LP | 0.64% | 824,679 | +39% | 2.4% | $13,912,335 |
| Siren, L.L.C. | 0.57% | 736,104 | 0% | 0.25% | $12,418,075 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.57% | 735,003 | +522% | 0% | $12,402,534 |
| STATE STREET CORP | 0.41% | 526,565 | 0% | $8,883,152 | |
| Affinity Asset Advisors, LLC | 0.31% | 400,000 | +14% | 0.33% | $6,748,000 |
| MORGAN STANLEY | 0.29% | 377,994 | +12% | 0% | $6,376,773 |
| UBS Group AG | 0.25% | 326,273 | -8.5% | 0% | $5,504,225 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.19% | 245,000 | +32% | 0.59% | $4,133,150 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.18% | 224,602 | 0% | $3,789,036 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Latest
Q2 2026
Rows shown
1-2 of 2